Gout

 

Addressing Misconceptions About Gout

October 29, 2020

In today's episode of the Rheumatology Network podcast Overdrive, we talk with Dr. Bradley Marder, medical director of nephrology for Horizon Therapeutics. Gout, he says, is not only a rheumatic disease that affects peripheral joints, it’s a disease that's systemic in nature and progressive. As a nephrologist, he sees gout as kidney disease. In today's episode of Overdrive, he explains why.

COVID Deaths Are High Among Waitlisted Kidney Transplant Patients

October 29, 2020

Although mortality rates for kidney transplant recipients with COVID-19 are known to be high, end stage kidney disease patients with COVID-19 appear to have a higher risk of mortality than patients with new kidneys.

Kidney Week Wraps With Presentations on COVID and Emerging Therapies

October 27, 2020

From COVID-19 presentations to emerging new therapies for chronic kidney disease, Dr. Bradley Marder, medical director of nephrology with Horizon Therapeutics, offers his take on the most memorable moments from the American Society for Nephrology/Kidney Week annual meeting which wrapped this week.

Allopurinol Doesn’t Slow Kidney Disease

October 23, 2020

The gout treatment allopurinol doesn't appear to slow the progression of chronic kidney disease in patients with moderate to severe loss of kidney function, shows a study presented yesterday at the American Society of Nephrology Kidney Week annual meeting.

Early Results for New Gout Treatments Presented at Kidney Week

October 23, 2020

In today's featured video, we talk with Dr. Brad Marder, medical director at Horizon Therapeutics, who shares with us the details of three studies presented at the American Society of Nephrology annual meeting which is taking place this week online. The studies highlight the preliminary results of clinical trials for new gout treatments. In this interview, he explains why this research is important.

COX-2 Inhibitors Best Traditional NSAIDS for Acute Gout

October 05, 2020

In patients with acute gout, cyclo-oxygenase-2 (COX-2) inhibitors, especially etoricoxib (Arcoxia, Merck & Co.), may result in a greater clinical response than traditional non-steroidal anti-inflammatory drugs (NSAIDs), according to a study published in BMJ Open.

Dapagliflozin Earns Breakthrough Therapy Designation for Chronic Kidney Disease

October 02, 2020

Dapagliflozin (Farxiga, AstraZeneca) has been granted breakthrough therapy designation by the U.S. Food and Drug Administration for patients with chronic kidney disease with and without type 2 diabetes. It is currently approved as a treatment to improve glycemic control in adults with type 2 diabetes.

Gout As Kidney Disease

October 02, 2020

Gout is not only an intermittent disease that affects peripheral joints, it’s a disease that's systemic in nature and progressive, says Dr. Bradley Marder, medical director of nephrology with Horizon Therapeutics. As a nephrologist, he sees gout as a kidney disease. In this interview, he explains why.

Adopting Right-Sized Patient Care in Rheumatology

August 28, 2020

In this week's one-on-one interview, we talk with Dr. Jeffrey Curtis of the University of Alabama. We spoke about the use of activity trackers as a tool to record and track arthritic flare-ups. The device has been found to be useful in improving patient care or as Dr. Curtis says, “we need to right-size care” by giving patients the right care at the right time.” In this interview, he explains how an activity tracker can make such a huge difference in the care patients receive.

Studies Link Gout Flares to Consuming Sodas

August 25, 2020

A systematic review and meta-analysis recently published the Journal of Human Nutrition and Dietetics finds that consuming sugar-sweetened beverages is significantly associated with increased serum uric acid concentrations associated with gout flares.

Talking Gout and Myths with Dr. Christopher Parker

May 29, 2020

In this week's news roundup from Rheumatology Network we continue our series on gout. Last week we featured a discussion with Dr. John D. Fitzgerald focusing on ACR's new gout treatment guidelines and this week, we talk with Dr. Christopher Parker, chief of rheumatology at Austin Diagnostic Clinic in Texas. Dr. Parker addresses mythbusters and patient engagement.

Highlights from ACR's 2020 Gout Guidelines

May 22, 2020

In this week's news roundup, we highlight two studies that examine risks associated with biologics used to treat rheumatic disease. We also highlight the 2020 treatment guidelines for gout issued this week by the American College of Rheumatology. In today's video, we feature an interview with John D. Fitzgerald, M.D., Ph.D., chief of rheumatology at Ronald Reagan UCLA Medical Center in Santa Monica. Dr. Fitzgerald served as the corresponding author of the guidelines.

The 2020 Treatment Guidelines for Gout

May 19, 2020

The American College of Rheumatology has updated its treatment guidelines for gout. The guideline includes 42 treatment recommendations, of which 16 are  now strongly recommended. They address standard treat-to-target urate lowering therapy, the use of allopurinol and more. In this slideshow, we highlight the 16 strongest recommendations. 

Rate of Serious Infections in Gout on the Rise

May 12, 2020

The rate of serious infections in people with gout, especially sepsis and pneumonia, is increasing, and certain patient characteristics and external factors are associated with both higher healthcare use and in-hospital mortality in these patients, according to one of the first U.S. studies to describe the epidemiology of hospitalized serious infections in gout.

Colchicine for Gout Gets a Clean Bill of Health

March 26, 2020

Colchicine, a first-line treatment option for acute gout, is associated with an increased risk of adverse events, such as diarrhea and other gastrointestinal symptoms, but not serious adverse events, finds a newly published systematic review and meta-analysis.

Febuxostat Hypersensitivity Risk in Gout Similar to Allopurinol

March 17, 2020

A new study published in the February 5 issue of Annals of the Rheumatic Diseases finds that allopurinol and febuxostat are associated with about the same risk of hypersensitivity reactions, as compared to gout patients treated with colchicine. The risk is even higher for women and diabetes patients, the authors wrote.